RecruitingRecruiting
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
NCT07856420 · Intra-Cellular Therapies, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment and an Open-label Long-term Extension Treatment With JNJ-99245354 (ITI-1284)
About this study
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder (GAD; a mental health condition defined by uncontrollable, and excessive worry about everyday events for a long period of time).
Eligibility criteria
Inclusion criteria:
* Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and at baseline
* Medically stable on the basis of clinical laboratory tests performed at screening
* History of inadequate response to at least 1 generalized anxiety disorder (GAD)-approved treatment taken at an adequate dose and duration as specified in the protocol for the treatment of ongoing GAD symptoms
* Is currently an outpatient and is anticipated to maintain outpatient status for the duration of the double blind (DB) treatment period of the trial
* Body mass index (BMI) within the range 19-40 kilogram per meter squared (kg/m\^2) (inclusive)
Exclusion criteria:
* Within the participant's lifetime, has one of the following confirmed diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) text revision (TR) psychiatric diagnoses: a. schizophrenia, schizoaffective disorder, schizophreniform disorder or other psychotic disorder; b. bipolar disorder
* Within 6 months of screening, has a confirmed DSM-5-TR psychiatric diagnosis other than GAD, including: a. other anxiety disorders (except simple phobias and social anxiety disorder); b. moderate or severe alcohol or substance use disorders (excluding nicotine); d. moderate or severe major depressive disorder; e. any other psychiatric condition (except for mild major depressive disorder \[MDD\]) that has been the main focus of treatment
* Montgomery-asberg depression rating scale (MADRS) total score greater than (\>)18 at screening or baseline
* Lifetime history of inadequate response to \>3 of the approved treatments for GAD at an adequate dose and for an adequate duration
* The participant is taking more than 1 anti depressive therapy (ADT) or is taking ADT + buspirone at screening, regardless of indication, and is unable or unwilling to discontinue additional ADT (or buspirone) prior to baseline
Study design
Enrollment target: 705 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-09-29
Estimated completion: 2030-09-28
Last updated: 2026-11-03
Interventions
Drug: JNJ-99245354Drug: Placebo
Primary outcomes
- • Change from Baseline to End of Week 6 in Hamilton Anxiety Rating (HAM-A) Scale Total Score (Baseline, Week 6)
Sponsor
Intra-Cellular Therapies, Inc. · industry
Contacts & investigators
ContactStudy Contact · contact · Participate-In-This-Study1@its.jnj.com · 844-434-4210
InvestigatorIntra-Cellular Therapies, Inc. Clinical Trial · study_director, Intra-Cellular Therapies, Inc.
All locations (4)
Inland Psychiatric Medical Group IncRecruiting
Temecula, California, United States
Nuovida Research CenterRecruiting
Miami, Florida, United States
Voltaire Clinical ResearchRecruiting
Springfield, Massachusetts, United States
Fieve Clinical Research IncRecruiting
New York, New York, United States